HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

Abstract
Multiple epidemiologic studies demonstrate associations between chronic beryllium disease (CBD), beryllium sensitization (BeS), and HLA-DPB1 alleles with a glutamic acid residue at position 69 (E69). Results suggest that the less-frequent E69 variants (non-*0201/*0202 alleles) might be associated with greater risk of CBD. In this study, we sought to define specific E69-carrying alleles and their amino acid sequences in the DP peptide binding groove, as well as their relationship to CBD and BeS risk, using the largest case control study to date. We enrolled 502 BeS/CBD subjects and 653 beryllium-exposed controls from three beryllium industries who gave informed consent for participation. Non-Hispanic white cases and controls were frequency-matched by industry. HLA-DPB1 genotypes were determined using sequence-specific primer PCR. The E69 alleles were tested for association with disease individually and grouped by amino acid structure using logistic regression. The results show that CBD cases were more likely than controls to carry a non-*02 E69 allele than an *02 E69, with odds ratios (95% confidence interval) ranging from 3.1 (2.1-4.5) to 3.9 (2.6-5.9) (p < 0.0001). Polymorphic amino acids at positions 84 and 11 were associated with CBD: DD versus GG, 2.8 (1.8-4.6), p < 0.0001; GD versus GG, 2.1 (1.5-2.8), p < 0.0001; LL versus GG, 3.2 (1.8-5.6), p < 0.0001; GL versus GG, 2.8 (2.1-3.8), p < 0.0001. Similar results were found within the BeS group and CBD/BeS combined group. We conclude that the less frequent E69 alleles confer more risk for CBD than does *0201. Recent studies examining how the composition and structure of the binding pockets influence peptide binding in MHC genes, as well of studies showing the topology of the TCR to likely bind DPB1 preferentially, give plausible biological rationale for these findings.
AuthorsLori J Silveira, Erin C McCanlies, Tasha E Fingerlin, Michael V Van Dyke, Margaret M Mroz, Matthew Strand, Andrew P Fontenot, Natalie Bowerman, Dana M Dabelea, Christine R Schuler, Ainsley Weston, Lisa A Maier
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 189 Issue 8 Pg. 4014-23 (Oct 15 2012) ISSN: 1550-6606 [Electronic] United States
PMID22972925 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • HLA-DP beta-Chains
  • HLA-DPB1 antigen
  • Inflammation Mediators
  • Beryllium
Topics
  • Alleles
  • Amino Acid Substitution (drug effects, genetics, immunology)
  • Berylliosis (genetics, immunology, pathology)
  • Beryllium (adverse effects, chemistry)
  • Case-Control Studies
  • Chronic Disease
  • Female
  • HLA-DP beta-Chains (chemistry, genetics)
  • Humans
  • Inflammation Mediators (adverse effects, chemistry)
  • Male
  • Polymorphism, Genetic (immunology)
  • Protein Binding (drug effects, genetics, immunology)
  • Respiratory Hypersensitivity (genetics, immunology, pathology)
  • Static Electricity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: